Characterization and Comparison of GITR Expression in Solid Tumors.

Autor: Vence L; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bucktrout SL; Cancer Immunology Discovery Unit, South San Francisco, California.; Parker Institute for Cancer Immunotherapy, San Francisco, California., Fernandez Curbelo I; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Blando J; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Smith BM; Cancer Immunology Discovery Unit, South San Francisco, California., Mahne AE; Cancer Immunology Discovery Unit, South San Francisco, California., Lin JC; Cancer Immunology Discovery Unit, South San Francisco, California.; Regeneron Pharmaceuticals Inc., Tarrytown, New York., Park T; Cancer Immunology Discovery Unit, South San Francisco, California., Pascua E; Cancer Immunology Discovery Unit, South San Francisco, California., Sai T; Cancer Immunology Discovery Unit, South San Francisco, California., Chaparro-Riggers J; Cancer Immunology Discovery Unit, South San Francisco, California., Subudhi SK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Scutti JB; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Higa MG; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhao H; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yadav SS; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maitra A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Allison JP; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sharma P; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas. PadSharma@mdanderson.org.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Nov 01; Vol. 25 (21), pp. 6501-6510. Date of Electronic Publication: 2019 Jul 29.

SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.

Autor: Berzaghi R; Experimental Oncology Unit, Department of Microbiology, Immunology and Parasitology, University of São Paulo, São Paulo, Brazil., Maia VS; Recepta Biopharma São Paulo, Brazil., Pereira FV; Laboratory of Cancer Immunobiology, University of São Paulo, São Paulo, Brazil., Melo FM; Immunology Department, Federal University of São Paulo, São Paulo, Brazil., Guedes MS; Experimental Oncology Unit, Department of Microbiology, Immunology and Parasitology, University of São Paulo, São Paulo, Brazil., Origassa CS; Laboratory of Cancer Immunobiology, University of São Paulo, São Paulo, Brazil., Scutti JB; Immunotherapy Platform, Department of Immunology, MD Anderson Cancer Center, Houston Texas, USA., Matsuo AL; Interdepartmental Group of Health Economics (Grides), Federal University of São Paulo, SP, Brazil., Câmara NO; Immunology Department, Biomedical Sciences Institute IV, University of São Paulo, São Paulo, Brazil., Rodrigues EG; Laboratory of Cancer Immunobiology, University of São Paulo, São Paulo, Brazil., Travassos LR; Experimental Oncology Unit, Department of Microbiology, Immunology and Parasitology, University of São Paulo, São Paulo, Brazil.; Recepta Biopharma São Paulo, Brazil.

Publikováno v: Scientific reports [Sci Rep] 2017 Jan 12; Vol. 7, pp. 40585. Date of Electronic Publication: 2017 Jan 12.